Literature DB >> 25083424

Expressions of D2-40, CK19, galectin-3, VEGF and EGFR in papillary thyroid carcinoma.

Lei Gong1, Ping Chen1, Xianjun Liu1, Ying Han1, Yanping Zhou1, Weidong Zhang1, Hong Li1, Chuanjia Li1, Jiang Xie1.   

Abstract

OBJECTIVE: To investigate the expressions of D2-40, CK19, galectin-3, VEGF, and EGFR in papillary thyroid carcinoma and their clinical significances.
METHODS: The expressions of D2-40, CK19, galectin-3, VEGF, and EGFR in 38 cases of papillary thyroid carcinoma and 12 cases of thyroid papillary hyperplasia were detected by immunohistochemical staining.
RESULTS: The positive expression rates of D2-40, CK19, Galectin-3, VEGF and EGFR in patients with papillary thyroid carcinoma were all significantly higher than those in patients with thyroid papillary hyperplasia (all P<0.05). The expressions of D2-40, VEGF, and EGFR in papillary thyroid carcinoma with lymph node metastasis were significantly higher than those without lymph node metastasis (P<0.05). The expressions of GK19 and galectin-3 showed no significant differences between the papillary thyroid carcinomas with and without lymph node metastasis (P>0.05).
CONCLUSIONS: The detection of D2-40, CK19, galectin-3, VEGF, and EGFR is helpful for the diagnosis and differential diagnosis of papillary thyroid carcinoma and thyroid papillary hyperplasia.

Entities:  

Keywords:  CK19; D2-40; EGFR; Thyroid neoplasms; VEGF; galectin-3; immunohistochemis; papillary carcinoma

Year:  2012        PMID: 25083424      PMCID: PMC4115709          DOI: 10.3978/j.issn.2227-684X.2012.03.02

Source DB:  PubMed          Journal:  Gland Surg        ISSN: 2227-684X


  29 in total

1.  Differential expression of cytokeratins in follicular variant of papillary carcinoma: an immunohistochemical study and its diagnostic utility.

Authors:  Z W Baloch; S Abraham; S Roberts; V A LiVolsi
Journal:  Hum Pathol       Date:  1999-10       Impact factor: 3.466

2.  Immunohistochemical diagnosis of papillary thyroid carcinoma.

Authors:  C C Cheung; S Ezzat; J L Freeman; I B Rosen; S L Asa
Journal:  Mod Pathol       Date:  2001-04       Impact factor: 7.842

Review 3.  Biomarkers for the diagnosis of thyroid cancer.

Authors:  Kruttibas Sethi; Siddik Sarkar; Subhasis Das; Biswanarayan Mohanty; Mahitosh Mandal
Journal:  J Exp Ther Oncol       Date:  2010

4.  Universal markers of thyroid malignancies: galectin-3, HBME-1, and cytokeratin-19.

Authors:  Figen Barut; Nilufer Onak Kandemir; Sibel Bektas; Burak Bahadir; Sevinc Keser; Sukru Oguz Ozdamar
Journal:  Endocr Pathol       Date:  2010-06       Impact factor: 3.943

5.  Differentiated thyroid cancer cell invasion is regulated through epidermal growth factor receptor-dependent activation of matrix metalloproteinase (MMP)-2/gelatinase A.

Authors:  Michael W Yeh; Jean-Philippe Rougier; Jin-Woo Park; Quan-Yang Duh; Mariwil Wong; Zena Werb; Orlo H Clark
Journal:  Endocr Relat Cancer       Date:  2006-12       Impact factor: 5.678

6.  Cytokeratin 19 and galectin-3 immunohistochemistry in the differential diagnosis of solitary thyroid nodules.

Authors:  M F Beesley; K M McLaren
Journal:  Histopathology       Date:  2002-09       Impact factor: 5.087

7.  Demonstration of a TGF-alpha-EGF-receptor autocrine loop and c-myc protein over-expression in papillary thyroid carcinomas.

Authors:  D R Haugen; L A Akslen; J E Varhaug; J R Lillehaug
Journal:  Int J Cancer       Date:  1993-08-19       Impact factor: 7.396

8.  Expression of vascular endothelial growth factor-C in benign and malignant thyroid tumors.

Authors:  Chung J Hung; David G Ginzinger; Raza Zarnegar; Hajime Kanauchi; Mariwil G Wong; Electron Kebebew; Orlo H Clark; Quan-Yang Duh
Journal:  J Clin Endocrinol Metab       Date:  2003-08       Impact factor: 5.958

9.  Distinction between papillary thyroid hyperplasia and papillary thyroid carcinoma by immunohistochemical staining for cytokeratin 19, galectin-3, and HBME-1.

Authors:  Mary B Casey; Christine M Lohse; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

10.  [Immunohistochemical identification of lymph vessels with D2-40 in diagnostic pathology].

Authors:  E Kaiserling
Journal:  Pathologe       Date:  2004-09       Impact factor: 1.011

View more
  9 in total

1.  Extracellular galectin-3 facilitates colon cancer cell migration and is related to the epidermal growth factor receptor.

Authors:  Keng-Liang Wu; Chung-Mou Kuo; Eng-Yen Huang; Hui-Mei Pan; Chao-Cheng Huang; Yi-Fan Chen; Chang-Chun Hsiao; Kuender D Yang
Journal:  Am J Transl Res       Date:  2018-08-15       Impact factor: 4.060

2.  miR-219-5p modulates cell growth of papillary thyroid carcinoma by targeting estrogen receptor α.

Authors:  Chen Huang; Zhaogeng Cai; Mingzhu Huang; Chaoming Mao; Qifa Zhang; Yi Lin; Xiaomei Zhang; Bi Tang; Yuqing Chen; Xiaojing Wang; Zhongqing Qian; Lei Ye; Yongde Peng; Huanbai Xu
Journal:  J Clin Endocrinol Metab       Date:  2014-11-25       Impact factor: 5.958

3.  CK19 IS A USEFUL MARKER IN DISTINGUISHING FOLLICULAR VARIANT OF PAPILLARY THYROID CARCINOMA FROM BENIGN THYROID LESIONS WITH FOLLICULAR GROWTH PATTERN.

Authors:  F Noroozinia; A Gheibi; B Ilkhanizadeh; A Abbasi
Journal:  Acta Endocrinol (Buchar)       Date:  2016 Oct-Dec       Impact factor: 0.877

4.  Gene expression profile analyze the molecular mechanism of CXCR7 regulating papillary thyroid carcinoma growth and metastasis.

Authors:  Hengwei Zhang; Xuyong Teng; Zhangyi Liu; Lei Zhang; Zhen Liu
Journal:  J Exp Clin Cancer Res       Date:  2015-02-12

5.  Galectin-3 may serve as a potential marker for diagnosis and prognosis in papillary thyroid carcinoma: a meta-analysis.

Authors:  Weiwei Tang; Congwei Huang; Chongyin Tang; Jin Xu; Hanjin Wang
Journal:  Onco Targets Ther       Date:  2016-01-22       Impact factor: 4.147

Review 6.  Galectin-3 Performance in Histologic a Cytologic Assessment of Thyroid Nodules: A Systematic Review and Meta-Analysis.

Authors:  Pierpaolo Trimboli; Camilla Virili; Francesco Romanelli; Anna Crescenzi; Luca Giovanella
Journal:  Int J Mol Sci       Date:  2017-08-11       Impact factor: 5.923

7.  Serum galectin-3 as a biomarker for screening, early diagnosis, prognosis and therapeutic effect evaluation of pancreatic cancer.

Authors:  Nan Yi; Xuying Zhao; Jie Ji; Minxue Xu; Yujie Jiao; Tianyang Qian; Shengze Zhu; Feng Jiang; Jianhua Chen; Mingbing Xiao
Journal:  J Cell Mol Med       Date:  2020-09-04       Impact factor: 5.310

8.  The Combined Utility of HBME-1 and Galectin-3 Immunohistochemistry and BRAF V600E Mutations in the Diagnosis of Papillary Thyroid Carcinoma.

Authors:  Subramaniam Ramkumar; Shanthakumari Sivanandham
Journal:  Cureus       Date:  2021-12-10

9.  Diagnostic significance of CK19, galectin-3, CD56, TPO and Ki67 expression and BRAF mutation in papillary thyroid carcinoma.

Authors:  Lihua Huang; Xuming Wang; Xuan Huang; Huawei Gui; Yan Li; Qiongxia Chen; Dongling Liu; Lijiang Liu
Journal:  Oncol Lett       Date:  2018-01-26       Impact factor: 2.967

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.